AQST Earnings

AQST reported its FY2025Q4 earnings on 2026-03-10, showcasing a revenue of against an estimate of 14.03M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.13 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following AQST's FY2025Q4 earnings announcement on 2026-03-10, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, AQST's stock price tends to shift by an average of -0.45% in the 10 days leading up to earnings and 4.69% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate AQST's annual revenue to reach 13.35M, while the EPS is projected at -0.14. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates revised downward by -0.04% over the past three months, indicating analyst expectation in the company's performance.

The correlation between AQST's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved revised downward by -0.04%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, AQST's stock price typically moves by -0.45% in the 10 days before its earnings and 4.69% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.14 and revenue of 13.35M.

The earnings call summary presents a mixed outlook. Positive aspects include the FDA approval track for Anaphylm, international expansion plans, and new patents. However, financial guidance indicates a significant EBITDA loss, and management was vague on pricing and partnerships. The Q&A revealed cautious optimism but also highlighted uncertainties, such as pricing and international strategies. Considering these factors, the overall sentiment is neutral, anticipating limited stock price movement.